Skip to main content
. Author manuscript; available in PMC: 2022 Apr 10.
Published in final edited form as: Sci Transl Med. 2021 Jan 20;13(577):eaba7401. doi: 10.1126/scitranslmed.aba7401

Figure 8. Therapy combining LY2606368 and GEM significantly improves survival in G3, but not SHH, MB.

Figure 8.

(A) Preclinical treatment protocol for mice with orthotopic G3 or SHHα MB xenografts for the data shown in B. (B) Mice harboring orthotopic G3 (yellow) or SHHα (red) MB xenografts were treated with vehicle (gray), LY2606368 (red), GEM (aqua), or a combination of LY2606368 with GEM (green). Bioluminescence measurements (left) and survival curves (right) were assessed. Comparisons of survival between combination-treated mice with each other group using Log-rank tests are shown with the number (n) of mice per group below each graph: P < 0.01667, *; P < 0.01, **; P < 0.005, ***; not significant (ns). (E-G) Toxicity was monitored twice weekly from the treatment groups as shown (legend applies to all graphs). Treatment duration is indicated by black bars. Blood counts (n=4 per group) from whole blood with ethylenediamine tetra-acetic acid were measured using a Forcyte Hematology Analyzer (Oxford Scientific). Shown are (E) neutrophils, (F) hemoglobin, and (G) platelets. The dotted orange line indicates an average normal murine parameter.